Disease-modifying osteoarthritis drugs: In vitro and in vivo data on the development of DMOADs under investigation

Expert Opinion on Investigational Drugs

Volumn 22, Issue 4, 2013, Pages 423-441

  Davies, Peter S E ^a   Graham, Simon M ^b   MacFarlane, Robert J ^b   Leonidou, Andreas ^c   Mantalaris, Athanasios ^d   Tsiridis, Eleftherios ^d,e,f  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Broadgreen University Hospital Orthopaedics   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Cartilage; Disease modifying osteoarthritis drug; Joint replacement; Joint space narrowing; Joint space width; Osteoarthritis; Subchondral bone; Synovium

Indexed keywords

AGG 523; ALENDRONIC ACID; ALPHA TOCOPHEROL; ALS 1 0635; BALICATIB; CALCITONIN; CELECOXIB; CHONDROITIN SULFATE; COLECALCIFEROL; COLLAGENASE 3; DIACEREIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DISEASE MODIFYING OSTEOARTHRITIS DRUG; DOXYCYCLINE; GLUCOSAMINE SULFATE; HYALURONIC ACID; INDOMETACIN; LICOFELONE; MATRIX METALLOPROTEINASE INHIBITOR; NAPROXEN; PG 116800; RISEDRONIC ACID; SD 6010; STRONTIUM RANELATE; TANOMASTAT; TIAPROFENIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HIP OSTEOARTHRITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JOINT SPACE NARROWING; KNEE OSTEOARTHRITIS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYNDROME; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; RADIOLOGICAL PARAMETERS; REVIEW; SPONDYLOSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; OSTEOARTHRITIS;

EID: 84875139909     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.770837     Document Type: Review

References (95)

1. NHS Evidence. Clinical Knowledge Summaries. Osteoarthritis. Available from: http://www.cks.nhs.uk/osteoarthritis/background-information/prevalence [Last accessed 15 November 2012]
2. Total hip and knee joint replacement procedures entered into the NJR, 2007/2008 to 2011/12, recorded by country in which the procedure took place. National Joint Registry. Available from: http://www.njrcentre.org.uk/NjrCentre/ Portals/0/Documents/England/Reports/9th-annual-report/jpg/Figure-1.4.jpg [Last accessed 15 November 2012]
3. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
4. National Institute for Health and Clinical Excellence. CG 59 Review of Osteoarthritis. Available from: http://www.nice.org.uk/nicemedia/live/11926/ 54907/54907.pdf [Last accessed 15 November 2012]
5. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken) 2012;64:465-74
6. Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005;64:1727-30
7. CHMP. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003440.pdf [Last accessed 8 January 2013]
8. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29
9. Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3-/-mice. Arthritis Rheum 2007;56:905-9
10. Wei S, Chen Y, Chung L, et al. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors. J Biol Chem 2003;278:9831-4
11. Leff RL, Elias I, Lonescu M, et al. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 2003;30:544-9
12. Krzeski P, Buckland-Wright C, Bálint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9:R109
13. Edwards D, Hoyer-hansen G, Blasi F, Sloane B. The Cancer Degradome. Proteases and cancer biology. 1st edition. Springer, New York; 2008
14. Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009;60:2008-18
15. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005;434:648-52
16. Majumdar MK, Askew R, Schelling S, et al. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 2007;56:3670-4
17. Chockalingham PS, Sun W, Rivera-Bermudez MA, et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011;19:315-23
18. Chubinskaya S, Hurtig M, Reuger DC. OP-1/BMP-7 in cartilage repair. Int Orthop 2007;31:773-81
19. Jelic M, Pecina M, Haspl M, et al. Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Factors 2001;19:101-13
20. Hunter Dj, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010;11:232
21. Moore EE, Bendele AM, Thompson DL, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005;13:623-31
22. Noyszewski EA, Wroblewski K, Dodge Gr, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum 2001;44:1089-95
23. Derfoul A, Miyoshi AD, Freeman DE, Tuan RS. Glucosamine promoted chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage 2007;15:646-55
24. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford) 2006;45:129-38
25. Gosset M, Berenbaum F, Levy A, et al. Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. Arthritis Res Ther 2006;8:R135
26. Tat SK, Pelletier JP, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007;9:R117
27. Imada K, Oka H, Kawasaki D, et al. Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull 2010;33:410-14
28. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):S39-46
29. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33
30. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86
31. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004;12:269-76
32. Wildi LM, Raynaild JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011;70:982-9
33. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23
34. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001;357:251-6
35. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008;148:268-77
36. Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183-91
37. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (oxford) 2007;46:731-5
38. Groves T. Report from BMJ post publication review meeting. Available from: http://www.bmj.com/content/341/bmj.c4675?tab=responses [Last accessed 15 Nov 2012]
39. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010;16:341-c4675
40. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomized, placebo-controlled trials. Osteoarthritis Cartilage 2008;16:254-60
41. Boileau C, Tat SK, Pelletier JP, et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for the protective effect against subchondral hone remodeling. Arthritis Res Ther 2008;10:R71
42. Fidelix TS, Soares B, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006(1):CD005117
43. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001;44:2539-47
44. Pham T, Le Hanaff A, Ravaud P, et al. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparion with diacerein and placebo in a 1 year randomized controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004;63:1611-17
45. Renapurkar DK, Mathur S, Rao J. Evaluation of efficacy and safety of diacerein in osteoarthritis of knee joint. Int J Pharm Bio Sci 2010;1:S54
46. Bischoff-Ferrari HA, Zhang Y, Kiel DP, Felson DT. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. Arthritis Rheum 2005;53:821-6
47. Mcalindon TE, Dawson-Hughes B, Driban J, et al. Clinical trial of vitamin D to reduce pain and structural progression of knee osteoarthritis (OA). Arthritis Rheum 2010;62(Suppl 10):706
48. Henrotin YE, Deberg MA, Crielaard JM, et al. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol 2006;33:1668-78
49. Henrotin Y, Labasse A, Zheng SX, et al. Effects of three avocado/soybean unsaponifiable mixtures on human articular chondrocytes metabolism. Clin Rheumatol 1998;17:31-9
50. Khayyal MT, El-Ghazaly M. The possible "chondroprotective" effect of the unsaponifiable constituents of avocado and soy in vitro. Drugs Exp Clin Res 1998;24:41-50
51. Lequesne M, Maheu E, Cadet C, Dreiser R. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002;47:50-8
52. Maheu E, Cadet C, Marty M, et al. Evaluation of the structure modifying effect of avocado-soybean unsaponifiables (ASU) in hip osteoarthritis(OA): results of the ERADIAS study, a 3-year prospective, randomized, double blind, placebo-controlled trial. Arthritis Rheum 2009;60(Suppl 10):847
53. Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000;43:1290-9
54. Hellio Le Graveand-Gastineau MP, Clemmer R, Redifer P. A 2-year randomized, double-blind, placebo-controlled, multicenter study of an oral selective iNOS inhibitor in subjects with symptomatic osteoarthritis of the knee. Osteoarthritis Cartilage 2012;20:S38
55. Manicourt D, Beaulieu A, Garnero P, et al. Effect of treatment with the cathepsin-k inhibitor, balicatib, on cartilage volume and biochemical markers of bone and cartilage degradation in patients with painful knee osteoarthritis. Osteoarthritis Cartilage 2007;15:C130
56. Rünger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012;66:e89-96
57. Pinney JR, Taylor C, Doan R, et al. Imaging longitudinal changes in articular cartilage and bone following doxycycline treatment in a rabbit anterior cruciate ligament transection model of osteoarthritis. Magn Reson Imaging 2012;30:271-82
58. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis. Results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25
59. Tiku ML, Shah R, Allison GT. Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem 2000;275:20069-76
60. Kaiki G, Yonezawa T, Sekido H, et al. Osteoarthritis induced by intra-articular hydrogen peroxide injection and running load. J Orthop Res 1990;8:731-40
61. Wluka AE, Stuckey S, Brand C, et al. Does Not Affect the Loss of Cartilage Volume in Knee Osteoarthritis: a 2 Year Double Blind Randomized Placebo Controlled Study. J Rheumatol 2002;29:2585-91
62. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicenter clinical trial using quantitative MRI. Ann Rheum Dis 2009;68:938-47
63. Husskisson EC, Berry H, Gishen P, et al. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. LINK study group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritis. J Rheumatol 1995;22:1941-6
64. Raynauld JP, Martel-Pelletier J, Haraoui B, et al. Risk factors predictive of joint replacement in a 2-year multicenter clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Ann Rheum Dis 2011;70:1382-8
65. Palmer RM, Hickery MS, Charles IG, et al. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993;193:398-405
66. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumour necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52:128-35
67. Ku G, Faust T, Lauffer LL, et al. Interleukin-1 beta converting enzyme inhibition blocks progression of type II collaged-induced arthritis in mice. Cytokine 1996;8:377-86
68. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthtitis Res Ther 2008;10:R67
69. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011;13:R125
70. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther 2011;13:124
71. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46
72. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumour necrosis factor inhibition in erosive/inflammatory osteoarthtitis of the hands. J Rheumatol 2007;34:1323-7
73. Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Preliminary results of a phase II placebo controlled trial with adalimumab in erosive hand osteoarthritis: predictors of erosive evolution and the potential effect of adalimumab in specific subgroups. Arthritis Rheum 2009;60(Suppl 10):856
74. Guler-Yuksel M, Allaart CF, Watt I, et al. Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage 2010;18:1256-62
75. Behrens F, Shepard N, Mitchell N. Alterations of rabbit articular cartilage by intra-articular injections of glucocorticoids. J Bone Joint Surg Am 1975;57:70-6
76. Pelletier JP, DiBattista JA, Raynauld JP, et al. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1, and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995;72:578-86
77. Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-7
78. Neogi T, Nevitt MC, Ensrud KE, et al. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008;67:1427-30
79. Bingham CO III, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507
80. Garnero P, Aronstein WS, Cohen SB, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008;16:660-6
81. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33
82. Buckland-Wright JC, Messent EA, Bingham CO III, et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64
83. Laslett LL, Dore DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomized controlled trial. Ann Rheum Dis 2012;71:1322-8
84. Fonseca JE, Brandi ML. Mechanism of action of strontium ranelate: what are the facts? Clin Cases Miner Mone Metab 2010;7:17-18
85. National Institute for Health and Clinical Excellence. Osteoporosis-primary prevention (TA160). Available from: http://www.nice.org.uk/ guidance/TA160 [Last accessed 15 November 2012]
86. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308
87. Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2011;14:236-43
88. Bruyere O, Delfierriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9
89. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomized placebo-controlled trial. Ann Rheum Dis 2013;72:179-86
90. Karsdal MA, Sondergaard BC, Arnold M, Christiansen C. Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann NY Acad Sci 2007;1117:181-95
91. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54:3205-11
92. Karsdal MA, Alexandersen P, John MR, et al. 64 Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from A 2-year phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011;19(Suppl 1):S35
93. Cicuttini FM, Jones G, Forbes A, Wluka AE. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 2004;63:1124-7
94. Conaghan PG, Hunter DJ, Maillefert JF, et al. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 2011;19:606-10
95. Hunter DJ, Li J, LaValley M, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 2007;9:R108